Under the terms of the agreement, Roche will provide R&D funding and milestone payments, and Entelos will conduct biosimulation research using its Metabolism PhysioLab® platform, which utilizes a 'virtual patient' approach to predict the effects of a drug on metabolic pathways and/or biomarkers.
This approach will be useful to Roche in analyzing existing preclinical and clinical data in order to optimize future clinical trials.
"With the increase of diabetes and obesity on a global scale, Roche is dedicated to developing new therapies to treat chronic metabolic disorders," said Jacques Mizrahi, global head of metabolic and vascular diseases at Roche.
"As part of this commitment, we believe Entelos’ biosimulation capabilities and disease knowledge will complement Roche’s expertise in metabolic diseases and provide us with cutting edge technology that will enhance our drug discovery programs."
"Entelos is extremely pleased to be expanding our collaboration with Roche, a world leader in the adoption and deployment of systems biology solutions," stated James Karis, president and CEO of Entelos.
"With our capability to create virtual patients and simulate human biology, we believe that Entelos brings a deeper understanding of human biology to the R&D process."